{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"PR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"12"}]}],"title":"VGPR"},{"categories":[{"measurements":[{"groupId":"OG000","value":"76"}]}],"title":"CR"}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Response was assessed according to International Myeloma Working Group (IMWG) criteria. Best response includes partial response (PR), very good partial response (VGPR), and complete response (CR). PR as per IMWG criteria is 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by ≥90% or to less than (\\<)200 mg per 24 hours. VGPR is serum and urine M-protein detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-protein plus urine M-protein level \\<100 mg per 24 hours. CR is negative immunofixation of serum and urine and disappearance of soft tissue plasmacytomas and \\<5% plasma cells in bone marrow. Percentages are rounded off to the nearest whole number.","groups":[{"description":"Participants received ixazomib 3 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 1 through 4, during which if the participants tolerated the initial dose, the dose was escalated to ixazomib 4 mg, capsules, orally, once on Days 1, 8, and 15 for Cycles 5 through 26, or until documented progressive disease (PD) or intolerable toxicity, whichever occurred first (cycle length=28 days).","id":"OG000","title":"Ixazomib"}],"paramType":"NUMBER","populationDescription":"Response-evaluable Population included a subset of the Efficacy Population and consisted of all participants who had a baseline\\&at least 1 postbaseline response assessment. As prespecified in the SAP, this population contained only one arm i.e., Ixazomib (efficacy outcomes data for the participants who received placebo before Protocol Amendment 8 was not collected per SAP), thus data is presented accordingly.","reportingStatus":"POSTED","timeFrame":"Up to 58.4 months","title":"Percentage of Participants Who Achieved or Maintained Best Response Before PD or up to Subsequent Therapy","type":"SECONDARY","unitOfMeasure":"percentage of participants"}